PYXS
Pyxis Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$124.18M
P/E Ratio
—
EPS
$-1.30
Beta
1.43
52W High
$5.55
52W Low
$0.97
50-Day MA
$1.77
200-Day MA
$2.25
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $13.86M |
| Gross Profit (TTM) | $11.47M |
| EBITDA | $-78.09M |
| Operating Margin | -600.00% |
| Return on Equity | -121.70% |
| Return on Assets | -51.90% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $0.85 |
| Price-to-Book | 3.97 |
| Price-to-Sales (TTM) | 8.96 |
| EV/Revenue | 7.32 |
| EV/EBITDA | 1.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $63.35M |
| Float | $40.72M |
| % Insiders | 22.13% |
| % Institutions | 33.84% |
Historical Volatility
HV 10-Day
109.57%
HV 20-Day
142.96%
HV 30-Day
126.39%
HV 60-Day
105.75%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($6.89 target)
1
Strong Buy7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026